Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27740532 | 0.86 | ADORA3 (0.45) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL27915695 | 0.85 | TTR (0.44) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL27495540 | 0.85 | ADORA3 (0.66) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL28807085 | 0.83 | ALDH1A1 (0.50) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL31179635 | 0.83 | ADORA3 (0.50) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL22365669 | 0.82 | MEN1 (0.56) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL28824893 | 0.80 | KDM4E (0.52) | MEN1KMT2AADORA3LMNAMAPT | |
| SCHEMBL17718332 | 0.79 | TTR (0.44) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL17718337 | 0.77 | TTR (0.39) | MEN1KMT2AHSP90AA1ADORA3LMNA | |
| SCHEMBL17718338 | 0.77 | TTR (0.39) | MEN1KMT2AHSP90AA1ADORA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912178-B1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INST BIOMEDICAL RES (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10160977-B2 | Super-enhancers and methods of use thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-12-25 | — | — | US | disclosed |
| US-20160237490-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-08-18 | — | — | US | disclosed |
| US-9181580-B2 | Super-enhancers and methods of use thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-11-10 | — | — | US | disclosed |
| US-9155724-B2 | Combination methods for treatment of disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2912178-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | The Whitehead Institute for Biomedical Research (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150111761-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2015-04-23 | — | — | US | disclosed |
| US-20140296218-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140287932-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | disclosed |
| WO-2014066848-A9 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014066848-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | disclosed |
| EP-2544686-A2 | COMBINATION METHODS FOR TREATMENT OF DISEASE | Whitehead Institute For Biomedical Research (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011097522-A2 | COMBINATION METHODS FOR TREATMENT OF DISEASE | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NFATC1, IRF3, BCOR | MEN1 3586/4885KMT2A 987/4885HSP90AA1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.